Staphylococcal infection of the mammary gland is an economically important disease of lactating ruminants and a cause for welfare concern. Control measures rely upon the use of antibiotics and disinfectants (6) . In many dairy herds, the prognosis for the elimination of staphylococcal infection by the treatment of clinical mastitis with antibiotics is exceedingly poor, with often less than a 15% cure rate. This problem may be attributed to the poor penetration of antibiotics and/or sequestration of the bacteria within the host cells, leading to a relapse of the infection once treatment with antibiotics has ended (11) . An alternative method of controlling the disease is required. A novel therapeutic or prophylactic approach to controlling staphylococcal mastitis would be to produce transgenic animals which could secrete the antistaphylococcal enzyme lysostaphin in their milk. Indeed, regulatory sequences from milk protein genes have been used to target the expression of human proteins to the mammary glands (1, 10) .
Lysostaphin is a cell wall-degrading enzyme which is secreted by Staphylococcus simulans biovar staphylolyticus, formerly designated S. staphylolyticus (28) . It hydrolyzes the pentaglycine links of the cell wall and so is active against staphylococcal species but inactive against bacteria of all other genera (16, 25, 27) . The gene encodes a preproenzyme which consists of three distinct regions: a typical signal peptide at the amino-terminal end, a series of tandem repeats, and then the mature lysostaphin (15, 26) . Conversion of prolysostaphin to the mature enzyme occurs extracellularly in cultures of S. simulans and involves removal of the tandem repeats. Lysostaphin has many attractive features for use as an antimicrobial agent: it has activity against nondividing as well as dividing cells, it is digested by intestinal proteinases, it has no oral toxicity, and it fails to elicit a significant immune response following oral administration to rats (12) . Furthermore, no resistance to therapy with recombinant lysostaphin has been observed for bovine mastitis (12) . Bramley and Foster (7) showed that 10 ,ug of commercial lysostaphin resulted in a significant reduction in the number of viable S. aureus cells in the mouse mammary gland. Expression at equivalent levels in transgenic mice should be sufficient to confer resistance to staphylococcal mastitis. Recombinant lysostaphin has been evaluated as a potential intramammary therapeutic in dairy cattle, and the minimal effective therapeutic dose was found to be 100 mg (24) . Although the enzyme, like antibiotics, is effective at eliminating bacteria present in bovine milk, it is unlikely to elicit a complete cure unless present within and around host cells.
The aim of the work in this communication was to assess whether the lysostaphin gene could be expressed in a eukaryotic system. We describe the cloning and modification of the bacterial gene and the expression of the modified gene in a eukaryotic cell-free system and in tissue culture cells.
MATERLALS AND METHODS
Bacterial strains, plasmids, and oligonucleotides. The bacterial strains and plasmids used are listed in Table 1 . The oligonucleotides used were as follows: 1, 5'-TlY11 l l TFPlGAAA CATCCATA [TAC I lll TlC-3'; 2, 5'-GGCCAACGTATF TAC7TFGCCTGTAAGAACA-3'; 3, 5'-AGCTITCCACCAT GGAGAAAACAAAA-3'; and 4, 3'-AGGTGGTACCTCT TTlTGTIT-5'. Staphylococcal strains were grown in ToddHewitt broth (Oxoid, Basingstoke, England). Escherichia coli strains were grown in Luria-Bertani (LB) medium. When required, ampicillin was used at a concentration of 50 jig ml-l. All the oligonucleotides were synthesized by the phosphoramidite method with an Applied Biosystems model 381A synthesizer. (8) was a modified version of the discontinuous system described by Laemmli (20) . Western immunoblotting was done by the method of Burnette (9), except that gelatin was used to block unbound sites. Polyclonal antiserum was raised in rabbits against commercial lysostaphin (Sigma) and was used in immunoblots at a dilution of 1:1,000.
Cell culture and DNA transfections. COS-7 cells, a simian kidney cell line transformed by an origin-defective mutant of simian virus 40, were cultured in Dulbecco's modified Eagle medium (Flow Laboratories) supplemented with 10% (vol/vol) fetal calf serum (GIBCO BRL) and glutamine 61.4 mM). The cells were seeded into 50-mm dishes at 6 x 10 cells per dish and grown in 3 ml of medium for 24 SDS and renature the enzyme (31) . Lysostaphin activity resulted in a clearing of the cells in the polyacrylamide gel.
RESULTS AND DISCUSSION
Cloning of the lysostaphin gene of S. simulans. Recsei et al. (26) and Heath et al. (14) had previously shown the lysostaphin gene to be located on a plasmid in S. simulans. Plasmid DNA from S. siniulans was partially digested with MboI, and fragments of 4 to 10 kb were isolated by sucrose gradient centrifugation and ligated to BamHI-digested and phosphatasetreated vector pBR322. The ligation mixture was transformed into E. coli HBIO, and transformants were selected on LB agar containing ampicillin. Resistant colonies were overlaid with soft agar containing heat-killed S. aureus M60 to screen for colonies expressing lysostaphin (26) . One colony, designated CHL1, produced clearing of the turbid overlay and contained a recombinant plasmid with an insert of approximately 6.7 kb. Oligonucleotides 1 and 2, based on sequences at the beginning and the end of the gene (15, 26) (Fig. la) (Lys) to an acidic (Glu) amino acid. The size of the MboII-HindIII fragment appeared to be similar to that expected from the sequence published by Heinrich et al. (15) but larger than that expected from the sequence published by Recsei et al. (26) . The 273-bp difference between the two sequences is due to the presence of seven extra tandem repeats in the pro-region of the sequence published by Heinrich et al. (15) . The ligation mixture was transformed into E. coli HBIO1, and ampicillinresistant colonies were screened for the presence of the construct with end-labelled oligonucleotide 1. Two colonies which appeared by restriction analysis to contain the correct construct were identified, but sequencing showed that the G at position +4 was absent in both constructs. The G was introduced by site-directed mutagenesis with a new batch of oligonucleotide 4 20 ,ul of S. aureus culture supernatant, and 1 ,ug of commercial lysostaphin, respectively). Figure 2 shows the translation products. Plasmid pCMLEM expressed several translation products (lane 2), few of which were expressed by the vector (lane 1). The largest predominant product, migrating at approximately 93 kDa on an SDSpolyacrylamide gel (lane 2), was predicted to be preprolysostaphin, the unprocessed form of lysostaphin (Fig. lb) . The smaller products had probably arisen from nonspecific degradation or were incomplete translation products. The 93-kDa band and the smaller bands disappeared when the translation mixture was treated with S. simulans culture supernatant (lane 3), which is known to convert secreted prolysostaphin to the mature enzyme (26) . A predominant band of 25 kDa was generated; this band was similar in size to mature lysostaphin, thus suggesting that the 93-kDa polypeptide was a precursor of lysostaphin. The band at approximately 86 kDa in lane 3 was probably the prepropeptide. Cleavage of the 93-kDa band was not observed in the presence of S. aureus M60 culture supernatant (lane 4). The addition of commercial lysostaphin to the translation mixture did not produce a radiolabelled band at 25 kDa (lane 5) , showing that the 25-kDa band in lane 2 did not result from [35S]methionine becoming entrapped in the unlabelled lysostaphin present in the S. simulans culture. The 93-kDa band was not produced when the pro-region encompassing the tandem repeats was deleted from the coding region, and a truncated product of approximately 30 kDa appeared (data not shown).
The size of preprolysostaphin, as estimated by SDS-PAGE, appeared for unknown reasons to be significantly larger than the size of an immature form of lysostaphin expressed in E. coli by Heinrich et al. (15) . The translation system used in the current experiment contained only the cellular components required for protein synthesis. The observed size difference could therefore not be due to posttranslational modifications. The aberrant size must be associated with the pro-region, as deletion of this region resulted in a truncated protein that migrated at the expected position on an SDS-polyacrylamide gel. Recsei et al. (26) have suggested that the apparent size anomaly reported for prolysostaphin in bacteria is probably due to below-average levels of binding of SDS to the protein because of the high content of glutamyl residues in the tandem repeats.
Translation was carried out in the presence of canine pancreatic microsomal vesicles to investigate initial posttranslational processing of preprolysostaphin. The translation products synthesized in the absence of microsomal vesicles were degraded by proteinase K (Fig. 3, lane 3) whereas protection from proteolysis was observed for translation products synthesized in the presence of vesicles (lane 4). Two proteins, of approximately 90 and 88 kDa, were protected from proteolysis. The former is probably prolysostaphin, and the latter is probably a derivative of the translocated enzyme. In a comparison of the intensities of lanes 1 and 4, it appeared that not all of the protein had been translocated into the vesicles. This result was probably due to the concentration and integrity of the membrane vesicles. When samples were pretreated with detergent to solubilize microsomal vesicles before proteinase K treatment, translation products were degraded (results not shown). These results show that the prokaryotic signal peptide is able to direct translation products across the membrane in a eukaryotic system. By analogy, Hall et al. (13) demonstrated that a prokaryotic signal peptide can direct the secretion of bacterial endoglucanase in mammalian cells. They also showed that replacing the prokaryotic signal sequence with a eukaryotic signal sequence did not increase the level of secreted protein. This observation suggests that a eukaryotic signal sequence may not increase the efficiency of secretion of prolysostaphin.
The low level of the preprolysostaphin translation product is probably not surprising, since the translation of mRNA ceases after 30 to 60 min of incubation with cell-free extracts (3). (Fig. 4, lane 1) . This band was not found in the culture medium or the total cell lysate from a 50-mm dish of cells transfected with the pEE14 vector (lane 2 or 3, respectively). A number of bands, including that of the 25-kDa mature lysostaphin, were detected in the total cell lysate from a 50-mm dish of cells transfected with pCMLEE (lane 4). A repeat experiment yielded similar results. The 90-kDa band present in the medium (lane 1) had probably not been released by nonspecific leakage or lysis of cells. If leakage or lysis had occurred, then the predominant 25-kDa band present in the pCMLEE lysate would also have been detected in the medium. In addition, deletion of the signal peptidase cleavage site (Ala-Ser-Glu; 15) from the lysostaphin gene affected the secretion of the enzyme (data not shown). These results provide further evidence that the prokaryotic signal sequence is functional in a eukaryotic system. The presence of processed lysostaphin in the COS-7 cell lysate suggested that preprolysostaphin was being processed intracellularly. Processing of preprolysostaphin in mammary cells could reduce the efficiency of secretion of the precursor protein in the mammary glands of a transgenic animal. Deletion of the pro-region did not appear to affect the secretion of the enzyme in COS-7 cells (data not shown). It may therefore be possible to maximize the secretion of lysostaphin by using the signal peptide to direct the secretion of mature lysostaphin.
The biological activity of the lysostaphin produced in COS-7 cells was investigated by spotting cell suspensions on agarose containing heat-killed S. alureuts, as shown in Fig. 5a . Cells transfected with pCMLEE produced an area of lysis due to the action of the enzyme, whereas cells transfected with the pEE14 vector did not. Similarly, medium from cells transfected with pCMLEE was shown to contain active enzyme, whereas activity was not detectable in medium from cells transfected with the pEE14 vector (results not shown). Analysis of the cell medium on a polyacrylamide gel containing heat-inactivated S. aureus and including approximately 0.1 U of the 25-kDa mature form as a size marker showed that a larger protein had weak antistaphylococcal activity (Fig. 5b) . This protein was probably the 90-kDa protein detected on the Western blot shown in Fig. 4 . The medium from the pEE14 transfection did not show antistaphylococcal activity in this system (results not shown). It is interesting that a precursor of lysostaphin appeared to be active. Indeed, Heinrich et al. (15) demonstrated that a precursor of lysostaphin is active in E. coli.
The lysostaphin gene joins a small group of prokaryotic genes which are known to be functional in mammalian cells. In particular, the coding sequence of cysE and cysM from Salmonella typhimulriium (29) and the coding sequence of cysE and cysK from E. coli (21) have been expressed in mammalian cells as a prerequisite to introducing the cysteine biosynthesis pathway into sheep for increasing wool production.
Conclusions. The bacterial lysostaphin gene has been modified to include an AUG initiation codon in a context favorable for the initiation of translation in a eukaryotic system. This construct has been expressed in a eukaryotic cell-free system and in COS-7 tissue culture cells. The bacterial signal peptide appeared to be functional and drove the secretion of active enzyme in COS-7 cells. The active secreted enzyme was probably prolysostaphin. Since (i) active lysostaphin can be secreted in a eukaryotic system, (ii) lysostaphin is active in the mammary glands, and (iii) vectors exist to target expression to the mammary glands, a transgenic approach to controlling staphylococcal mastitis would appear to be feasible. 
